Lemaire-Hurtel Anne-Sophie, Goullé Jean-Pierre, Alvarez Jean-Claude, Mura Patrick, Verstraete Alain G
CHU d'Amiens, laboratoire de pharmacologie et toxicologie, centre de biologie humaine, 80054 Amiens, France.
Faculté de médecine et de pharmacie de Rouen, laboratoire de toxicologie, 76000 Rouen, France.
Presse Med. 2015 Oct;44(10):1055-63. doi: 10.1016/j.lpm.2015.03.007. Epub 2015 May 5.
Some drugs are known to impair driving because they can change the vision or hearing, and/or disrupt the intellectual or motor abilities: impaired vigilance, sedation, disinhibition effect, the coordination of movement disorders and the balance. The doctor during prescribing and the pharmacist during deliverance of drug treatment should inform their patients of the potential risks of drugs on driving or operating machinery. The driver has direct responsibility, who hired him and him alone, to follow the medical advice received. The pictograms on the outer packaging of medicinal products intended to classify substances according to their risk driving: The driver can whether to observe simple precautions (level one "be prudent"), or follow the advice of a health professional (level two "be very careful"), or if it is totally not drive (level three "danger caution: do not drive"). This classification only evaluates the intrinsic danger of drugs but not the individual variability. Medicines should be taken into account also the conditions for which the medication is prescribed. It is important to inform the patient on several points.
一些药物已知会影响驾驶，因为它们会改变视力或听力，和/或扰乱智力或运动能力，如警觉性受损、镇静、去抑制作用、运动协调障碍和平衡失调。开处方的医生和提供药物治疗的药剂师应告知患者药物对驾驶或操作机械的潜在风险。司机有直接责任，且只有他自己，遵循所收到的医疗建议。药品外包装上的象形图用于根据药物对驾驶的风险对物质进行分类：司机可以选择采取简单预防措施（一级“谨慎”），或遵循健康专业人员的建议（二级“非常小心”），或者完全不驾驶（三级“危险警告：请勿驾驶”）。这种分类仅评估药物的内在危险性，而非个体差异。还应考虑药物所针对的病症。向患者说明几个要点很重要
